Results 161 to 170 of about 125,916 (291)

Cadherin‐26 Facilitates Transepithelial Migration of Eosinophils in Eosinophilic Chronic Rhinosinusitis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Eosinophilic chronic rhinosinusitis with nasal polyps (eCRSwNP) is characterized by persistent sinonasal inflammation and marked eosinophilic infiltration. Although the relationship between eosinophils and NP formation has been extensively studied, the mechanisms governing eosinophil transepithelial migration into the nasal mucosa ...
Yeong‐In Jo   +7 more
wiley   +1 more source

Polydatin alleviates mitochondrial damage and apoptosis of lung epithelial cells by inhibiting toll‐like receptor 4‐dependent macrophage activation in asthma

open access: yesAnimal Models and Experimental Medicine, EarlyView.
The alleviation of asthma by polydatin is dependent on the blockage of the toll‐like receptor 4 (TLR4)/P2X7R synergy in macrophages. The blockage of the TLR4/P2X7R synergy results in decreased release and secretion of interleukin‐1β (IL‐1β) and IL‐18. In epithelial cells, low IL‐1β and IL‐18 levels inhibit mitochondrial damage and apoptosis.
Guangxing Li   +9 more
wiley   +1 more source

Inflammatory response to retrotransposons drives tumor drug resistance that can be prevented by reverse transcriptase inhibitors. [PDF]

open access: yesProc Natl Acad Sci U S A, 2022
Novototskaya-Vlasova KA   +10 more
europepmc   +1 more source

Combined Delivery of CuO Nanoparticles and HIF‐1α Inhibitor Acriflavine for Synergistic Local Treatment of Glioblastoma

open access: yesAdvanced NanoBiomed Research, EarlyView.
Encapsulated acriflavine (ACF) and copper oxide nanoparticles (CuO NPs) are coreleased from coaxial nanofibers, producing synergistic antiglioblastoma multiforme effects. ACF suppresses the hypoxia‐inducible factor 1α pathway related to many downstream factors for tumor growth, while CuO NPs generate reactive oxygen species that assist cuproptosis ...
Daewoo Han   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy